Cargando…
Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination
BACKGROUND: Efficacy of cancer vaccines may be limited due to immune escape mechanisms like loss or mutation of target antigens. Here, we analyzed 10 HLA-A2 positive patients with acute myeloid leukemia (AML) for loss or mutations of the WT1 epitope or epitope flanking sequences that may abolish pro...
Autores principales: | Busse, Antonia, Letsch, Anne, Scheibenbogen, Carmen, Nonnenmacher, Anika, Ochsenreither, Sebastian, Thiel, Eckhard, Keilholz, Ulrich |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844374/ https://www.ncbi.nlm.nih.gov/pubmed/20092642 http://dx.doi.org/10.1186/1479-5876-8-5 |
Ejemplares similares
-
Long term efficacy of WT1 peptide vaccine in patients with WT1 overexpressing hematopoeitic and solid malignancies
por: Letsch, Anne, et al.
Publicado: (2013) -
Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo
por: Benteyn, Daphné, et al.
Publicado: (2013) -
The Wilms’ tumor (WT1) gene: Methods and protocols
por: Agrawal, Suraksha
Publicado: (2018) -
Wilms’ Tumour gene 1 (WT1) as an immunotherapeutic target
por: Coosemans, A.
Publicado: (2011) -
Wilms Tumor-1 (WT1) rs16754 Polymorphism
por: Sookaromdee, Pathum, et al.
Publicado: (2019)